MX2020014031A - Proteinas heterodimericas y usos de las mismas. - Google Patents
Proteinas heterodimericas y usos de las mismas.Info
- Publication number
- MX2020014031A MX2020014031A MX2020014031A MX2020014031A MX2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A
- Authority
- MX
- Mexico
- Prior art keywords
- heterodimeric proteins
- proteins
- immunotherapies
- autoimmunity
- cancer
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688167P | 2018-06-21 | 2018-06-21 | |
| US201862703248P | 2018-07-25 | 2018-07-25 | |
| PCT/US2019/038451 WO2019246508A1 (en) | 2018-06-21 | 2019-06-21 | Heterodimeric proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020014031A true MX2020014031A (es) | 2021-05-12 |
Family
ID=68983045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020014031A MX2020014031A (es) | 2018-06-21 | 2019-06-21 | Proteinas heterodimericas y usos de las mismas. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10995127B2 (enExample) |
| EP (1) | EP3810172A4 (enExample) |
| JP (3) | JP7439372B2 (enExample) |
| KR (1) | KR20210025054A (enExample) |
| CN (1) | CN112566650A (enExample) |
| AU (1) | AU2019290192A1 (enExample) |
| BR (1) | BR112020026112A2 (enExample) |
| CA (1) | CA3103975A1 (enExample) |
| MX (1) | MX2020014031A (enExample) |
| WO (1) | WO2019246508A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112566650A (zh) * | 2018-06-21 | 2021-03-26 | 沙塔克实验室有限公司 | 异二聚体蛋白及其用途 |
| CA3149583A1 (en) * | 2019-08-30 | 2021-03-04 | Shattuck Labs, Inc. | Chimeric proteins in autoimmunity |
| WO2021202354A1 (en) * | 2020-03-30 | 2021-10-07 | Proviva Therapeutics (Hong Kong) Limited | Il-2/il-15 compositions and methods of use thereof |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| US20240262893A1 (en) | 2021-05-12 | 2024-08-08 | Applied Biomedical Science Institute | Binding polypeptides against sars cov-2 and uses thereof |
| JP2024521987A (ja) | 2021-05-12 | 2024-06-05 | アプライド バイオメディカル サイエンス インスティチュート | ジスルフィド結合した結合ポリペプチドのスクリーニング及び発現の方法 |
| EP4511054A2 (en) * | 2022-04-20 | 2025-02-26 | Neptune Biosciences LLC | Orthogonal il-21 receptor/cytokine systems |
| CA3256783A1 (en) | 2022-05-16 | 2023-11-23 | Enkefalos Biosciences, Llc | Blood-brain barrier translocation peptides and associated molecules and their methods of use |
| WO2024019984A1 (en) * | 2022-07-18 | 2024-01-25 | Cargo Therapeutics, Inc. | Cytokine receptor switch polypeptides and uses thereof |
| AU2023379740A1 (en) | 2022-11-16 | 2025-05-29 | Applied Biomedical Science Institute | Fusion polypeptides and binding peptides and methods for producing and using same |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
| WO2025133115A1 (en) * | 2023-12-21 | 2025-06-26 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising il-35 |
| WO2025140436A1 (zh) * | 2023-12-27 | 2025-07-03 | 上海药明生物技术有限公司 | 重组il-27蛋白及其制备方法 |
| CN117986386B (zh) * | 2024-02-06 | 2024-11-29 | 康立泰生物医药(青岛)有限公司 | 重组人白细胞介素-35及其制备方法和应用 |
| US20260035414A1 (en) * | 2024-08-01 | 2026-02-05 | Twilight Bioscience, Inc. | Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE196297T1 (de) * | 1994-05-18 | 2000-09-15 | Synthetic Peptides Inc | Heterodimere trägerzusammensetzung von immunogenen polypeptiden und verfahren zu deren verwendung |
| IT1274350B (it) * | 1994-12-06 | 1997-07-17 | Angeletti P Ist Richerche Bio | Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130 |
| BR9707589A (pt) * | 1996-02-20 | 2000-01-04 | Applied Research Systems | Proteìna hìbrida, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica e processos para produzir proteìna hìbrida e para induzir maturação folicular. |
| ES2590912T3 (es) * | 1997-12-08 | 2016-11-24 | Merck Patent Gmbh | Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| MXPA02001417A (es) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| DE60123998T2 (de) * | 2000-08-08 | 2007-09-06 | Zymogenetics, Inc., Seattle | Lösliche zcyctor 11 cytokinrezeptoren |
| ATE498633T1 (de) * | 2004-07-09 | 2011-03-15 | Variety Children S Hospital D B A Miami Children S Hospital | Materialien und verfahren zur stimulierung des immunsystems |
| EP2072527A1 (en) * | 2007-12-21 | 2009-06-24 | Altonabiotec AG | Fusion polypeptides comprising a SHBG dimerization component and uses thereof |
| EP2478013B1 (en) * | 2009-09-16 | 2018-10-24 | F.Hoffmann-La Roche Ag | Coiled coil and/or tether containing protein complexes and uses thereof |
| CA2785907A1 (en) * | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| EP4012714A1 (en) * | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| JP6594855B2 (ja) * | 2013-03-15 | 2019-10-23 | ゼンコア インコーポレイテッド | ヘテロ二量体タンパク質 |
| US10017545B2 (en) * | 2013-06-03 | 2018-07-10 | University Of Maryland, College Park | Compositions and vaccines comprising vesicles and methods of using the same |
| MX2017003472A (es) * | 2014-09-17 | 2017-10-31 | Genentech Inc | Inmunoconjugados que comprenden anticuerpos anti-her2. |
| CN104403004B (zh) * | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| EP4406604A3 (en) * | 2015-03-05 | 2024-10-23 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| KR20180030085A (ko) * | 2015-07-26 | 2018-03-21 | 몰레큘러 템플레이츠, 인코퍼레이션. | 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자 |
| JP6981973B2 (ja) * | 2015-10-01 | 2021-12-17 | ヒート バイオロジクス，インコーポレイテッド | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| IL260021B (en) * | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| BR112019005964A2 (pt) * | 2016-09-27 | 2019-06-18 | Epicentrx, Inc. | proteínas de fusão imunomoduladoras |
| US12447213B2 (en) * | 2016-10-07 | 2025-10-21 | The Broad Institute, Inc. | Modulation of novel immune checkpoint targets |
| US20190367579A1 (en) * | 2017-02-27 | 2019-12-05 | Shattuck Labs, Inc. | Tigit- and light-based chimeric proteins |
| CN112566650A (zh) * | 2018-06-21 | 2021-03-26 | 沙塔克实验室有限公司 | 异二聚体蛋白及其用途 |
| US11098093B2 (en) * | 2019-01-07 | 2021-08-24 | Shattuck Labs, Inc. | Heterodimeric proteins for modulating gamma delta T cells |
| CA3149583A1 (en) * | 2019-08-30 | 2021-03-04 | Shattuck Labs, Inc. | Chimeric proteins in autoimmunity |
-
2019
- 2019-06-21 CN CN201980053803.4A patent/CN112566650A/zh active Pending
- 2019-06-21 WO PCT/US2019/038451 patent/WO2019246508A1/en not_active Ceased
- 2019-06-21 MX MX2020014031A patent/MX2020014031A/es unknown
- 2019-06-21 CA CA3103975A patent/CA3103975A1/en active Pending
- 2019-06-21 JP JP2020571400A patent/JP7439372B2/ja active Active
- 2019-06-21 AU AU2019290192A patent/AU2019290192A1/en not_active Abandoned
- 2019-06-21 EP EP19823119.3A patent/EP3810172A4/en not_active Withdrawn
- 2019-06-21 KR KR1020217001659A patent/KR20210025054A/ko not_active Ceased
- 2019-06-21 BR BR112020026112-2A patent/BR112020026112A2/pt unknown
- 2019-09-16 US US16/571,853 patent/US10995127B2/en active Active
-
2021
- 2021-03-24 US US17/211,180 patent/US11780897B2/en active Active
-
2023
- 2023-01-17 US US18/155,218 patent/US20230220030A1/en not_active Abandoned
- 2023-06-15 JP JP2023098823A patent/JP7452932B2/ja active Active
-
2024
- 2024-03-04 JP JP2024032407A patent/JP2024057087A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11780897B2 (en) | 2023-10-10 |
| JP2024057087A (ja) | 2024-04-23 |
| WO2019246508A1 (en) | 2019-12-26 |
| BR112020026112A2 (pt) | 2021-04-06 |
| US10995127B2 (en) | 2021-05-04 |
| EP3810172A4 (en) | 2022-04-20 |
| JP7452932B2 (ja) | 2024-03-19 |
| US20230220030A1 (en) | 2023-07-13 |
| US20210214409A1 (en) | 2021-07-15 |
| JP2021527700A (ja) | 2021-10-14 |
| JP2023116718A (ja) | 2023-08-22 |
| CN112566650A (zh) | 2021-03-26 |
| US20200079831A1 (en) | 2020-03-12 |
| AU2019290192A1 (en) | 2021-01-07 |
| CA3103975A1 (en) | 2019-12-26 |
| KR20210025054A (ko) | 2021-03-08 |
| EP3810172A1 (en) | 2021-04-28 |
| JP7439372B2 (ja) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020014031A (es) | Proteinas heterodimericas y usos de las mismas. | |
| ZA201905488B (en) | Tigit- and light-based chimeric proteins | |
| PH12018500694A1 (en) | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins | |
| PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| MY203971A (en) | Anti-lag-3 antibodies and compositions | |
| PH12017501483A1 (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
| WO2018190719A3 (en) | Anti-sirp alpha antibodies | |
| MX2022007140A (es) | Terapias combinadas dirigidas a proteina 1 de muerte celular programada (pd-1), proteina 3 de dominio de mucina y dominio inmunoglobulina de los linfocitos t (tim-3), y gen de activacion de linfocitos 3 (lag-3). | |
| PH12020550051A1 (en) | Glp-1 compositions and uses thereof | |
| CL2018003582A1 (es) | Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567) | |
| CR20200114A (es) | Compuestos que contienen pirazolopirimidinona y sus usos | |
| EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
| WO2017134302A3 (en) | Targeted therapeutic agents and uses thereof | |
| PH12016501107A1 (en) | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
| MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
| ZA201905023B (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| PH12021551475A1 (en) | Heterodimeric proteins for modulating gamma delta t cells | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| MX2021002286A (es) | Terapias de combinacion. | |
| MX2024005649A (es) | Proteinas quimericas basadas en sirp1a y cd40l. | |
| MX2019009293A (es) | Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos. |